

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

TIMER

RRID:SCR_018737

Type: Tool

Proper Citation

TIMER (RRID:SCR_018737)

Resource Information

URL: <https://cistrome.shinyapps.io/timer/>

Proper Citation: TIMER (RRID:SCR_018737)

Description: Web server for comprehensive analysis of tumor infiltrating immune cells. Web tool for systematical analysis of immune infiltrates across diverse cancer types. Allows users to input function specific parameters, with resulting figures dynamically displayed to access tumor immunological, clinical, and genomic features.

Abbreviations: TIMER

Synonyms: Tumor IMmune Estimation Resource

Resource Type: analysis service resource, data access protocol, production service resource, service resource, software resource, web service

Defining Citation: [PMID:29092952](#)

Keywords: Tumor, tumor infiltrating immune cell, immune cell, cell, analysis, cancer cell, cancer type, tumor immunological feature, tumor genomic feature, display

Funding: Dana-Farber Cancer Institute ;
National Natural Science Foundation of China ;
NCI CA180980

Availability: Free, Freely available

Resource Name: TIMER

Resource ID: SCR_018737

Record Creation Time: 20220129T080341+0000

Record Last Update: 20260905T132841+0000

Ratings and Alerts

No rating or validation information has been found for TIMER.

No alerts have been found for TIMER.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3010 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Manoukian P, et al. (2026) Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. *Cancer research*, 86(3), 571.

Xia P, et al. (2026) CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma. *NPJ precision oncology*, 10(1).

Solern?? LM, et al. (2026) Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. *Frontiers in medicine*, 13, 1864843.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. *Cellular signalling*, 141, 112368.

Wang XX, et al. (2026) Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. *Journal for immunotherapy of cancer*, 14(2).

Yoo J, et al. (2026) Spatial Transcriptomic Landscape of Brain Metastases from Triple-Negative Breast Cancer: Comparison of Primary Tumor and Brain Metastases Using Spatial Analysis. *Cancer research and treatment*, 58(1), 182.

Peri E, et al. (2026) Decoding the Molecular Drivers of Epithelial to Mesenchymal Transition in Breast Cancer: Insights into Epithelial Plasticity and Microenvironment Crosstalk. *Biology*, 15(3).

Pan P, et al. (2026) The MEOX1-PAX1 axis coordinately regulates tumor cell malignancy and Treg differentiation in glioblastoma. *Scientific reports*, 16(1).

Tian W, et al. (2026) The role of ASIC2 in glioma progression: implications for prognosis and therapeutic targeting. *PeerJ*, 14, e20583.

Kishan R, et al. (2026) Ablation of cancer cell secreted neuropeptide PTHLH/PTHrP provokes anti-tumor immunity in murine tongue squamous cell carcinoma. *Scientific reports*, 16(1), 6920.

Amelimojarad M, et al. (2026) ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK-STAT3 Signaling. *Cancer medicine*, 15(2), e71543.

Niu R, et al. (2026) Disruption of the NDC80-Nek2 axis suppresses glioblastoma stemness and enhances therapeutic efficacy. *Journal of translational medicine*, 24(1).

Rao Z, et al. (2026) Palmitic acid-triggered B7H3 palmitoylation promotes immune escape. *Nature communications*, 17(1), 1810.

Lu L, et al. (2026) The pseudouridine synthase PUS7 is associated with stemness and represents a potential therapeutic target in triple-negative breast cancer cells. *Scientific reports*, 16(1), 2411.

Guo J, et al. (2026) Pan-cancer and multi-omics analyses reveal the diagnostic and prognostic value of BAZ2B in cancer. *Scientific reports*, 16(1), 3578.

Gao L, et al. (2026) Therapeutic potential of CDK8 inhibitor combined with sorafenib for hepatocellular carcinoma: mechanistic insights and in vitro validation. *European journal of medical research*, 31(1), 219.

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. *Cancer research communications*, 6(1), 17.

Yin J, et al. (2026) Regulating Tumor Metabolic Reprogramming with Biomimetic Co-Delivery of Simvastatin and Kynureninase for Immunotherapy. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(12), e08107.

Yang J, et al. (2026) Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH-Mutant Glioma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(3), e03866.

Qin H, et al. (2026) EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a multi-omics and validation study. *Journal of translational medicine*, 24(1).